MARKED-UP COPY OF AMENDMENT TO CLAIMS

4. (Amended) The DDS compound according to [any one of claims 1 to 3] claim 1, wherein the carboxy(C_{1-4}) alkyldextran polyalcohol modified with a saccharide compound is formed by binding a saccharide compound and a carboxy(C_{1-4})alkyldextran polyalcohol by means of a linker.

8. (Amended) The DDS compound according to claim 6 [or 7], which is obtainable by binding the residue of drug compound to the carboxy(C_{1-4})alkyldextran polyalcohol which is produced by binding the saccharide compound or a linker bound with the saccharide compound to a part of carboxyl groups of the carboxy(C_{1-4})alkyl moiety of the carboxy(C_{1-4})alkyldextran polyalcohol.

11. (Amended) The DDS compound according to claim 9 [or 10], which is obtainable by modifying with a saccharide compound a carboxy(C_{1-4})alkyldextran polyalcohol produced by binding a residue of drug compound to a part of carboxyl groups of the carboxy(C_{1-4})alkyl moiety of the carboxy(C_{1-4})alkyldextran polyalcohol by means of a spacer comprising one amino acid or a spacer comprising 2 to 8 amino acids linked by peptide bond(s).

12. (Amended) The DDS compounds according to [any one of claims 1 to 11] claim 1, wherein the saccharide compound is galactose or galactosamine, or a derivative thereof.

13. (Amended) The DDS compounds according to [any one of claims 1 to 12] claim 1, wherein the saccharide compound is N-acetylgalactosamine[,].

15. (Amended) The DDS compounds according to [any one of claims 1 to 14] claim 1, wherein the dextran polyalcohol that constitutes the carboxy(C_{1-4})alkyldextran polyalcohol is a dextran polyalcohol which is obtained by treating dextran under conditions that enable substantially complete polyalcoholization.

16. (Amended) The DDS compound according to [any one of claims 1 to 15] claim 1, wherein the carboxy(C_{1-4})alkyldextran polyalcohol is carboxymethyldextran polyalcohol.

17. (Amended) The DDS compound according to [any one of claims 1 to 16] claim 1, wherein the drug compound is an antineoplastic agent or an anti-inflammatory agent.

19. (Amended) The DDS compound according to [any one of claims 1 to 17] claim 1, wherein the drug compound is (1S,9S)-1-amino-9-ethyl-5-fluoro-2,3-dihydro-9-hydroxy-4-methyl-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinoline-10,13(9H,15H)-dione.

21. (Amended) A carboxy(C_{1-14})alkyldextran polyalcohol for use in the manufacture of the DDS compound according to [any one of claims 1 to 20] claim 1.

27. (Amended) The method according to [any one of claims 24 to 26] claim 24, wherein the hydrolysate is the drug compound.

28. (Amended) The method according to [any one of claims 24 to 26] claim 24, wherein the hydrolysate is a compound comprising the residue of drug compound bound with a part of the spacer.

30. (Amended) The method according to [any one of claims 24 to 29] claim 24, wherein the polymer carrier is a polysaccharide derivative having carboxyl groups.

32. (Amended) The method according to [any one of claims 24 to 31] claim 24, wherein the drug compound introduced to the DDS compound is an antineoplastic agent or an anti-inflammatory agent.

33. (Amended) The method according to [any one of claims 24 to 32] claim 24, wherein the spacer is a tetrapeptide represented by -Gly-Gly-Phe-Gly- from the N-terminal or a tetrapeptide represented by -Gly-Gly-Gly-Phe- from the N-terminal.

34. (Amended) The method according to [any one of claims 24 to 32] claim 24, wherein the spacer is a group represented by -Gly-Gly-Phe-Gly-HN-Y'-CH_2-O-CO- from the N-terminal or a group represented by -Gly-Gly-Gly-Phe-NH-Y'-CH_2-O-CO- from the N-terminal wherein Y' represents p-phenylene group.

35. (Amended) The method according to [any one of claims 24 to 34] claim 24, wherein the peptidase is α-chymotrypsin or papain.

36. (Amended) The method according to [any one of claims 24 to 35] claim 24, wherein the drug compound is (1S,9S)-1-amino-9-ethyl-5-fluoro-2,3-dihydro-9-hydroxy-4-methyl-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinoline-10,13(9H,15H)-dione.

37. (Amended) The method according to [any one of claims 24 to 29] claim 24, which is used for measurement of a DDS compound in which a carboxy(C_{1-4})alkyldextran polyalcohol and (1S,9S)-1-amino-9-ethyl-5-fluoro-2,3-dihydro-9-hydroxy-4-methyl-1H,12H-benzo[de]pyrano3'4':6,7]indolizino[1,2-b]quinoline-10,13(9H,15H)-dione are bound to each other by means of a spacer comprising a tetrapeptide represented by -Gly-Gly-Phe-Gly- or a tetrapeptide represented by -Gly-Gly-Gly-Phe- from the N-terminal.